Use of extracorporeal techniques in the removal of dabigatran

Neeharika Muddana; Culver Thuyanh; Ali Nayer; Khaled Nashar; Luis M. Ortega

doi:10.1097/MJT.0000000000000082

Use of extracorporeal techniques in the removal of dabigatran

Neeharika Muddana, Culver Thuyanh, Ali Nayer, Khaled Nashar, Luis M. Ortega

Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Dabigatran is a novel direct thrombin inhibitor that has proven effective in the prevention of vascular events in patients with nonvalvular atrial fibrillation. Not much is known about the clearance capability with extracorporeal techniques of dabigatran. This review showcases the pharmacokinetics and a perusal of the current literature regarding cases that involved the clearance of the drug in patients with normal renal function and end-stage renal disease. Renal replacement therapy represents a therapeutic option to eliminate dabigatran and decreased the risk of bleeding in patients undergoing emergent surgical procedures on dabigatran.

Original language	English (US)
Pages (from-to)	e485-e488
Journal	American journal of therapeutics
Volume	23
Issue number	2
DOIs	https://doi.org/10.1097/MJT.0000000000000082
State	Published - Mar 1 2016

Keywords

bleeding
dabigatran
dialysis
renal replacement therapy
thrombin inhibitors
toxicity

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1097/MJT.0000000000000082

Fingerprint Dive into the research topics of 'Use of extracorporeal techniques in the removal of dabigatran'. Together they form a unique fingerprint.

Cite this

@article{ca75ee7d124a42f9ae858466211a70f1,

title = "Use of extracorporeal techniques in the removal of dabigatran",

abstract = "Dabigatran is a novel direct thrombin inhibitor that has proven effective in the prevention of vascular events in patients with nonvalvular atrial fibrillation. Not much is known about the clearance capability with extracorporeal techniques of dabigatran. This review showcases the pharmacokinetics and a perusal of the current literature regarding cases that involved the clearance of the drug in patients with normal renal function and end-stage renal disease. Renal replacement therapy represents a therapeutic option to eliminate dabigatran and decreased the risk of bleeding in patients undergoing emergent surgical procedures on dabigatran.",

keywords = "bleeding, dabigatran, dialysis, renal replacement therapy, thrombin inhibitors, toxicity",

author = "Neeharika Muddana and Culver Thuyanh and Ali Nayer and Khaled Nashar and Ortega, {Luis M.}",

year = "2016",

month = mar,

day = "1",

doi = "10.1097/MJT.0000000000000082",

language = "English (US)",

volume = "23",

pages = "e485--e488",

journal = "American Journal of Therapeutics",

issn = "1075-2765",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Use of extracorporeal techniques in the removal of dabigatran

AU - Muddana, Neeharika

AU - Thuyanh, Culver

AU - Nayer, Ali

AU - Nashar, Khaled

AU - Ortega, Luis M.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Dabigatran is a novel direct thrombin inhibitor that has proven effective in the prevention of vascular events in patients with nonvalvular atrial fibrillation. Not much is known about the clearance capability with extracorporeal techniques of dabigatran. This review showcases the pharmacokinetics and a perusal of the current literature regarding cases that involved the clearance of the drug in patients with normal renal function and end-stage renal disease. Renal replacement therapy represents a therapeutic option to eliminate dabigatran and decreased the risk of bleeding in patients undergoing emergent surgical procedures on dabigatran.

AB - Dabigatran is a novel direct thrombin inhibitor that has proven effective in the prevention of vascular events in patients with nonvalvular atrial fibrillation. Not much is known about the clearance capability with extracorporeal techniques of dabigatran. This review showcases the pharmacokinetics and a perusal of the current literature regarding cases that involved the clearance of the drug in patients with normal renal function and end-stage renal disease. Renal replacement therapy represents a therapeutic option to eliminate dabigatran and decreased the risk of bleeding in patients undergoing emergent surgical procedures on dabigatran.

KW - bleeding

KW - dabigatran

KW - dialysis

KW - renal replacement therapy

KW - thrombin inhibitors

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=84903428721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903428721&partnerID=8YFLogxK

U2 - 10.1097/MJT.0000000000000082

DO - 10.1097/MJT.0000000000000082

M3 - Review article

C2 - 24987943

AN - SCOPUS:84903428721

VL - 23

SP - e485-e488

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 2

ER -